Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Dow
Medtronic
Merck
Baxter

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 5,614,520

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 5,614,520 protect, and when does it expire?

Patent 5,614,520 protects ULORIC and is included in one NDA.

This patent has sixteen patent family members in twelve countries.

Summary for Patent: 5,614,520
Title: 2-arylthiazole derivatives and pharmaceutical composition thereof
Abstract:Pharmaceutical compositions for treating gout or hyperuricemia and containing a new categorized compound, i.e. 2-arylthiazole derivatives, as an active ingredient, are provided. The 2-arylthiazole derivatives in the present invention are represented by the following formula (I): ##STR1## wherein Ar is an unsubstituted or substituted pyridyl, thienyl, furyl, naphthyl or phenyl group; X is a hydrogen atom, alkyl group or carboxyl group which may be protected, and Y is a hydrogen atom, alkyl group, or a hydroxyl or carbonyl group which may be protected. Furthermore, novel compounds included in the 2-arylthiazole derivatives and pharmaceutically acceptable salts thereof are provided.
Inventor(s): Kondo; Shiro (Hachioji, JP), Fukushima; Hisashi (Hino, JP), Hasegawa; Masaichi (Hino, JP), Tsuchimoto; Masahiro (Hino, JP), Nagata; Ikuo (Hino, JP), Osada; Yoshio (Hino, JP), Komoriya; Keiji (Hachioji, JP), Yamaguchi; Hisao (Hino, JP)
Assignee: Teijin Limited (Osaka, JP)
Application Number:08/380,214
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,614,520
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 5,614,520

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-001 Feb 13, 2009 AB RX Yes No   Start Trial   Start Trial Y Y CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA   Start Trial
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 AB RX Yes Yes   Start Trial   Start Trial Y Y CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,614,520

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2-330147Nov 30, 1990
Japan3-216586Aug 02, 1991

International Family Members for US Patent 5,614,520

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 142494   Start Trial
Australia 645867   Start Trial
Australia 8952291   Start Trial
Canada 2073981   Start Trial
Germany 122008000051   Start Trial
Germany 69122084   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Baxter
AstraZeneca
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.